All In Biotech

Drug Trial Radar · NCT06743126

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Jan 14, 2025

Primary completion

Jan 2028

Study completion Aug 12, 2032

Sponsor

Lead sponsor
Immatics US, Inc.Industry
Sponsor type
Industry
First posted
Dec 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma or mucosal melanoma (MM). For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/

Conditions

  • Melanoma, Cutaneous Malignant
  • Mucosal Melanoma

Interventions

  • IMA203Biological

    one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy

  • nivolumab plus relatlimabBiological

    in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

  • lifileucelBiological

    in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

  • nivolumabBiological

    in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

  • pembrolizumabBiological

    in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

  • ipilimumabBiological

    in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

  • DacarbazineDrug

    in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

  • temozolomideDrug

    in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

  • paclitaxelDrug

    in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

  • paclitaxel plus carboplatinDrug

    in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

  • Albumin-Bound PaclitaxelDrug

    in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival assessed by BICRTime frame: up to 5 years post first treatment of last patient

Locations

71 sites in 6 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Phoenix, Arizona · Recruiting

  • Honor Health Research Institute

    Scottsdale, Arizona · Recruiting

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • UCLA Hematology/Oncology

    Los Angeles, California · Recruiting

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California · Recruiting

  • Stanford Cancer Center

    Stanford, California · Recruiting

  • University of Colorado, Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Mayo Clinic Florida

    Jacksonville, Florida · Recruiting

  • University of Miami - Sylvester Comprehensive Cancer Cente

    Miami, Florida · Recruiting

  • AdventHealth, Orlando

    Orlando, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • University of MD Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Atlantic Health System/Morristown Medical Center

    Morristown, New Jersey · Recruiting

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University of Rochester

    Rochester, New York · Recruiting

  • UNC Hospitals, The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Cleveland Clinic, Taussig Cancer Institute

    Cleveland, Ohio · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • Providence Cancer Institute Franz Clinic

    Portland, Oregon · Recruiting

  • Lehigh Valley Topper Cancer Institute

    Allentown, Pennsylvania · Recruiting

  • University of Pennsylvania, Abramson Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Thomas Jeffersion University, Sidney Kimmel Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Avera Cancer Institute

    Sioux Falls, South Dakota · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Baylor University

    Dallas, Texas · Recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah · Recruiting

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.